Humira approved for juvenile rheumatoid arthritis
Abbott's Humira (adalimumab) had been approved by the food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis...
Abbott's Humira (adalimumab) has been approved by the Food and Drug Administration for its sixth indication, juvenile rheumatoid arthritis.
JVA joins other indications including chronic plaque psoriasis, rheumatoid arthritis in adults, and Crohn's disease.
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Recent Videos
Related Content
